Skip to main content

Advertisement

SpringerLink
Log in

Combined lysosomal protein transmembrane 4 beta-35 and argininosuccinate synthetase expression predicts clinical outcome in hepatocellular carcinoma patients

  • Original Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Purpose

The newly-identified lysosomal protein transmembrane 4 beta-35 (LAPTM4B-35) plays important roles in tumor progression and metastasis, while argininosuccinate synthetase (ASS) provides arginine as an indispensable nutrient for hepatocellular carcinoma (HCC). The present study investigated the clinical significance of the coexpression of LAPTM4B-35 and ASS in HCC patients on determining the prognosis.

Methods

Immunohistochemistry was used to evaluate the expression of LAPTM4B-35 and ASS in HCC tissues and paired noncancerous liver samples from 71 patients. The correlation of combined LAPTM4B-35 and ASS expression with selected clinicopathologic parameters was assessed with the chi-squared test. Patient survival and differences in survival were determined by the Kaplan-Meier method and the log-rank test. A Cox regression analysis was adopted for a multivariate analysis of the prognostic factors.

Results

Combined LAPTM4B-35 and ASS expression was significantly associated with TNM stage and portal vein invasion. In addition, patients with HCCs expressing both LAPTM4B-35 and ASS exhibited both markedly poorer overall survival (OS) and disease-free survival (DFS) (both P < 0.001). According to the multivariate analyses, combined LAPTM4B-35 and ASS expression was found to be an independent prognostic factor for OS and DFS (P = 0.039 and P = 0.035, respectively).

Conclusion

The overexpression of LAPTM4B-35 in combination with positive ASS expression is a negative prognostic marker for HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.

    Article  PubMed  Google Scholar 

  2. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001;33:62–75.

    Article  PubMed  CAS  Google Scholar 

  3. Vainer GW, Pikarsky E, Ben-Neriah Y. Contradictory functions of NF-kappaB in liver physiology and cancer. Cancer Lett 2008;267:182–188.

    Article  PubMed  CAS  Google Scholar 

  4. Douglass EC. Hepatic malignancies in childhood and adolescence (hepatoblastoma, hepatocellular carcinoma, and embryonal sarcoma). Cancer Treat Res 1997;92:201–212.

    PubMed  CAS  Google Scholar 

  5. Shao GZ, Zhou RL, Zhang QY, Zhang Y, Liu JJ, Rui JA, et al. Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene 2003;22:5060–5069.

    Article  PubMed  CAS  Google Scholar 

  6. Peng C, Zhou RL, Shao GZ, Rui JA, Wang SB, Lin M, et al. Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma. World J Gastroenterol 2005;11:2704–2708.

    PubMed  CAS  Google Scholar 

  7. Yang H, Xiong FX, Lin M, Yang Y, Nie X, Zhou RL. LAPTM 4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol 2010;136:275–281.

    Article  PubMed  CAS  Google Scholar 

  8. Liu X, Xiong F, Wei X, Yang H, Zhou R. LAPTM4B-35, a novel tetratransmembrane protein and its PPRP motif play critical roles in proliferation and metastatic potential of hepatocellular carcinoma cells. Cancer Sci 2009;100:2335–2340.

    Article  PubMed  CAS  Google Scholar 

  9. Ito T, Shiraki K, Sekoguchi K, Yamanaka T, Sugimoto K, Takase K, et al. Hepatocellular carcinoma associated with adult-type citrullinemia. Dig Dis Sci 2000;45:2203–2206.

    Article  PubMed  CAS  Google Scholar 

  10. Dillon BJ, Prieto VG, Curley SA, Ensor CM, Holtsberg FW, Bomalaski JS, et al. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer 2004;100:826–833.

    Article  PubMed  CAS  Google Scholar 

  11. Miyazaki K, Takaku H, Umeda M, Fujita T, Huang WD, Kimura T, et al. Potent growth inhibition of human tumor cells in culture by arginine deiminase purified from a culture medium of a Mycoplasma-infected cell line. Cancer Res 1990;50:4522–4527.

    PubMed  CAS  Google Scholar 

  12. Wheatley DN, Campbell E. Arginine deprivation, growth inhibition and tumour cell death: 3. Deficient utilisation of citrulline by malignant cells. Br J Cancer 2003;89:573–576.

    Article  PubMed  CAS  Google Scholar 

  13. Grabon W. Arginine as a crucial amino acid in carcinogenesis and tumor growth. Postepy Hig Med Dosw (Online) 2006;60:483–489.

    Google Scholar 

  14. Yang Y, Yang H, McNutt MA, Xiong F, Nie X, Li L, et al. LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma. Oncol Rep 2008;20:1077–1083.

    PubMed  Google Scholar 

  15. Morris SM Jr. Regulation of enzymes of the urea cycle and arginine metabolism. Annu Rev Nutr 2002;22:87–105.

    Article  PubMed  CAS  Google Scholar 

  16. Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem J 1998;336(Pt 1):1–17.

    PubMed  CAS  Google Scholar 

  17. Husson A, Brasse-Lagnel C, Fairand A, Renouf S, Lavoinne A. Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle. Eur J Biochem 2003;270:1887–1899.

    Article  PubMed  CAS  Google Scholar 

  18. Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA. Pegylated arginine deiminase (ADI-SS PEG20 000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res 2002;62:5443–5450.

    PubMed  CAS  Google Scholar 

  19. Yoon CY, Shim YJ, Kim EH, Lee JH, Won NH, Kim JH, et al. Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. Int J Cancer 2007;120:897–905.

    Article  PubMed  CAS  Google Scholar 

  20. Sugimura K, Ohno T, Kusuyama T, Azuma I. High sensitivity of human melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase in vitro. Melanoma Res 1992;2:191–196.

    Article  PubMed  CAS  Google Scholar 

  21. Scott L, Lamb J, Smith S, Wheatley DN. Single amino acid (arginine) deprivation: rapid and selective death of cultured transformed and malignant cells. Br J Cancer 2000;83:800–810.

    Article  PubMed  CAS  Google Scholar 

  22. Wheatley DN, Campbell E. Arginine catabolism, liver extracts and cancer. Pathol Oncol Res 2002;8:18–25.

    Article  PubMed  CAS  Google Scholar 

  23. Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S, et al. Arginine deprivation as a targeted therapy for cancer. Curr Pharm Des 2008;14:1049–1057.

    Article  PubMed  CAS  Google Scholar 

  24. Cheng PN, Lam TL, Lam WM, Tsui SM, Cheng AW, Lo WH, et al. Pegylated recombinant human arginase (rhArg-peg5 000 mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res 2007;67:309–317.

    Article  PubMed  CAS  Google Scholar 

  25. Izzo F, Montella M, Orlando AP, Nasti G, Beneduce G, Castello G, et al. Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis. J Gastroenterol Hepatol 2007;22:86–91.

    Article  PubMed  CAS  Google Scholar 

  26. Qin LX, Tang ZY. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol 2004;130: 497–513.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cell Biology, School of Basic Medical Sciences, Peking University, Beijing, 100191, PR China

    Hua Yang, Ming Lin, Fuxia Xiong & Rouli Zhou

  2. Department of Pathology, School of Basic Medical Sciences, Peking University, Beijing, 100191, PR China

    Yu Yang & Michael A. Mcnutt

  3. Department of Pathology, Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, PR China

    Xiu Nie

Authors
  1. Hua Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ming Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fuxia Xiong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yu Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiu Nie
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michael A. Mcnutt
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rouli Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

H.Y. and M.L. contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, H., Lin, M., Xiong, F. et al. Combined lysosomal protein transmembrane 4 beta-35 and argininosuccinate synthetase expression predicts clinical outcome in hepatocellular carcinoma patients. Surg Today 41, 810–817 (2011). https://doi.org/10.1007/s00595-010-4338-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-010-4338-5

Keywords

Search

Navigation